In his latest Clinical Update, Gary Culliton looks at recent developments in the field of Alzheimer’s disease, including investigations into whether neuro-cardiovascular instability risk factors increase the risk of developing the condition.
White matter damage in Alzheimer’s disease
August 6, 2011 By Leave a Comment
Dr Laurence O’Dwyer writes that by increasing our understanding of how white matter is damaged in Alzheimer’s disease, we can improve our chances of developing drugs to counter the condition Although the mechanisms of Alzheimer’s disease are not well under-stood, advances in brain imaging tools are making it possible to track its onset and progression [...]
Change to name of Ebixa product range
January 5, 2011 By Leave a Comment
The Alzheimer’s disease (AD) medication Ebixa Oral Drops is undergoing a change of name from this month. The current name, Ebixa 10mg/g Oral Drops, Solution, is changing at the request of the European Medicines Agency (EMA) to more accurately reflect the actual dosing of the Ebixa oral solution pump device. The new name will be [...]